Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats

References

• Humbert M, Lau EM, Montani D, Jais X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189–2208. doi:10.1161/CIRCULATIONAHA.114.006974. PMID:25602947.
   PubMed Web of Science ®Google Scholar
• Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(3):261–272. doi:10.1164/rccm.201201-0164OC. PMID:22679007.
   PubMed Web of Science ®Google Scholar
• Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120(11):992–1007. doi:10.1161/CIRCULATIONAHA.106.674028. PMID:19752350.
   PubMed Web of Science ®Google Scholar
• White RJ, Lannan KL, Phipps RP. Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed. Drug Discov Today. 2014;19(8):1226–1229. doi:10.1016/j.drudis.2014.04.008. PMID:24769253.
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297(6):L1013–1032. doi:10.1152/ajplung.00217.2009. PMID:19748998.
   PubMed Web of Science ®Google Scholar
• White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L583–590. doi:10.1152/ajplung.00321.2006. PMID:17586694.
   PubMed Web of Science ®Google Scholar
• Lafranconi WM, Huxtable RJ. Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochem Pharmacol. 1984;33(15):2479–2484. doi:10.1016/0006-2952(84)90721-4. PMID:6087830.
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Kiyatake K, Tatsumi K, Sugito K, Kakusaka I, Yamagata S, et al. Bioactivation of monocrotaline by P-450 3A in rat liver. J Cardiovasc Pharmacol. 1997;30(1):124–129. doi:10.1097/00005344-199707000-00018. PMID:9268231.
   PubMed Web of Science ®Google Scholar
• Lalich JJ, Merkow L. Pulmonary arteritis produced in rat by feeding Crotalaria spectabilis. Lab Invest; J. Tech. Methods Pathol. 1961;10:744–750.
   Google Scholar
• Taylor DW, Wilson DW, Lame MW, Dunston SD, Jones AD, Segall HJ. Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells. Toxicol Appl Pharmacol. 1997;143(1):196–204. doi:10.1006/taap.1996.8083. PMID:9073608.
   PubMed Web of Science ®Google Scholar
• Reid MJ, Lame MW, Morin D, Wilson DW, Segall HJ. Involvement of cytochrome P450 3A in the metabolism and covalent binding of 14C-monocrotaline in rat liver microsomes. J Biochem Mol Toxicol. 1998;12(3):157–166. doi:10.1002/(SICI)1099-0461(1998)12:3<157::AID-JBT4>3.0.CO;2-K. PMID:9522275.
   PubMed Web of Science ®Google Scholar
• Mattocks AR, Jukes R. Trapping and measurement of short-lived alkylating agents in a recirculating flow system. Chem Biol Interact. 1990;76(1):19–30. doi:10.1016/0009-2797(90)90031-H. PMID:2393942.
   PubMed Web of Science ®Google Scholar
• Yan CC, Huxtable RJ. Effects of monocrotaline, a pyrrolizidine alkaloid, on glutathione metabolism in the rat. Biochem Pharmacol. 1996;51(3):375–379. doi:10.1016/0006-2952(95)02189-2. PMID:8573205.
   PubMed Web of Science ®Google Scholar
• Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L363–369. doi:10.1152/ajplung.00212.2011. PMID:21964406.
   PubMed Web of Science ®Google Scholar
• Schultze AE, Roth RA. Chronic pulmonary hypertension–the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev. 1998;1(4):271–346. doi:10.1080/10937409809524557. PMID:9776954.
   PubMed Web of Science ®Google Scholar
• Lee YS, Byun J, Kim JA, Lee JS, Kim KL, Suh YL, et al. Monocrotaline-induced pulmonary hypertension correlates with upregulation of connective tissue growth factor expression in the lung. Exp Mol Med. 2005;37(1):27–35. doi:10.1038/emm.2005.4. PMID:15761249.
   PubMed Web of Science ®Google Scholar
• Lame MW, Jones AD, Wilson DW, Dunston SK, Segall HJ. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem. 2000;275(37):29091–29099. doi:10.1074/jbc.M001372200. PMID:10875930.
   PubMed Web of Science ®Google Scholar
• Thomas HC, Lame MW, Morin D, Wilson DW, Segall HJ. Prolonged cell-cycle arrest associated with altered cdc2 kinase in monocrotaline pyrrole-treated pulmonary artery endothelial cells. Am J Respir Cell Mol Biol. 1998;19(1):129–142. doi:10.1165/ajrcmb.19.1.2895. PMID:9651189.
   PubMed Web of Science ®Google Scholar
• Lappin PB, Ross KL, King LE, Fraker PJ, Roth RA. The response of pulmonary vascular endothelial cells to monocrotaline pyrrole: cell proliferation and DNA synthesis in vitro and in vivo. Toxicol Appl Pharmacol. 1998;150(1):37–48. doi:10.1006/taap.1998.8398. PMID:9630451.
   PubMed Web of Science ®Google Scholar
• Thomas HC, Lame MW, Wilson DW, Segall HJ. Cell cycle alterations associated with covalent binding of monocrotaline pyrrole to pulmonary artery endothelial cell DNA. Toxicol Appl Pharmacol. 1996;141(1):319–329. doi:10.1016/S0041-008X(96)80038-X. PMID:8917705.
   PubMed Web of Science ®Google Scholar
• Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005;96(4):442–450. doi:10.1161/01.RES.0000157672.70560.7b. PMID:15692087.
   PubMed Web of Science ®Google Scholar
• Deng Y, Wang S, Yang A, Stewart DJ. Strain-dependent differences in arterial medial and intimal remodelling in monocrotaline-induced pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;191:A1968.
   Google Scholar
• Roth RA, Dotzlaf LA, Baranyi B, Kuo CH, Hook JB. Effect of monocrotaline ingestion on liver, kidney, and lung of rats. Toxicol Appl Pharmacol. 1981;60(2):193–203. doi:10.1016/0041-008X(91)90223-2.
   PubMed Web of Science ®Google Scholar
• Copple BL, Banes A, Ganey PE, Roth RA. Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. Toxicol Sci.: An Official Journal of the Society of Toxicology. 2002;65(2):309–318. doi:10.1093/toxsci/65.2.309.
   Google Scholar
• DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29(6):1779–1791. doi:10.1002/hep.510290615. PMID:10347121.
   PubMed Web of Science ®Google Scholar
• Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin. 2002;20(3):441–457, doi:10.1016/S0733-8651(02)00017-6. PMID:12371012.
   PubMedGoogle Scholar
• Dumitrascu R, Koebrich S, Dony E, Weissmann N, Savai R, Pullamsetti SS, et al. Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm Med. 2008;8(1):1–15. doi:10.1186/1471-2466-8-25. PMID:18221550.
   PubMedGoogle Scholar
• Molteni A, Ward WF, Ts'ao CH, Solliday NH. Monocrotaline pneumotoxicity in mice. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):149–155. doi:10.1007/BF02899076. PMID:2570481.
   PubMedGoogle Scholar
• Hayashi S, Mitsumori K, Imaida K, Imazawa T, Yasuhara K, Uneyama C, et al. Establishment of an animal model for pulmonary fibrosis in mice using monocrotaline. Toxicol Pathol. 1995;23(1):63–71. doi:10.1177/019262339502300108. PMID:7770701.
   PubMed Web of Science ®Google Scholar
• Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol. 2008;295(2):H677–690. doi:10.1152/ajpheart.91519.2007. PMID:18552156.
   PubMed Web of Science ®Google Scholar
• Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, et al. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016;110:319–330. doi:10.1093/cvr/cvw054. PMID:26980205.
   PubMed Web of Science ®Google Scholar
• Yao J, Li CG, Gong LK, Feng CC, Li CZ, Gao M, et al. Hepatic cytochrome P450s play a major role in monocrotaline-induced renal toxicity in mice. Acta Pharmacol Sin. 2014;35(2):292–300. doi:10.1038/aps.2013.145. PMID:24362331.
   PubMed Web of Science ®Google Scholar
• Carstens LA, Allen JR. Arterial degeneration and glomerular hyalinization in the kidney of monocrotaline-intoxicated rats. Am J Pathol. 1970;60(1):75–92. PMID:4193443.
   PubMed Web of Science ®Google Scholar
• Kurozumi T, Tanaka K, Kido M, Shoyama Y. Monocrotaline-induced renal lesions. Exp Mol Pathol. 1983;39(3):377–386. doi:10.1016/0014-4800(83)90066-7. PMID:6416892.
   PubMed Web of Science ®Google Scholar
• Liu RM, Dickinson DA. Decreased synthetic capacity underlies the age-associated decline in glutathione content in Fisher 344 rats. Antioxid Redox Signal. 2003;5(5):529–536. doi:10.1089/152308603770310176. PMID:14580307.
   PubMed Web of Science ®Google Scholar
• Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, et al. Translating research into improved patient care in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;195(5):583–595. doi:10.1164/rccm.201607-1515PP. PMID:27649290.
   PubMed Web of Science ®Google Scholar